At ValitaCell we are driven by continuous innovation and R&D.
We develop cutting-edge technologies and simple but innovative solutions to support the biopharmaceutical industry to deliver new generation medicines to more patients, faster and with greater safety.
Facilitates and accelerates high-throughput protein aggregation screening.
- Non-monomer IgG from 0.5% – >/=20%
- Differentiate natural dimerization
- Broad molecular weight range
Facilitates and accelerates high-throughput tagged protein screening.
- Polyhistidine-tag (His-tag)
- More tag formats in development
- Wide MW proteins spectrum
Facilitates and accelerates high-throughput screening of non-Fc containing IgGs.
- Not reliant on IgG Fc interactions
- Targeting the Fab domain of an IgG
Find here the main benefits of the products currently in development
Add, mix & read
No sample preparation, short incubation, no wash steps
Low capex requirement
96/384 well plates
Easy integration in any automation workflow
From discovery to manufacturing